These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2201046)

  • 1. Immune modifiers in the treatment of bladder cancer.
    Morales A
    Prog Clin Biol Res; 1990; 350():25-33. PubMed ID: 2201046
    [No Abstract]   [Full Text] [Related]  

  • 2. [ BCG-immunotherapy and bladder cancer].
    Rischmann P
    Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors.
    Ibraheim EH; El Kappany H; Nigam VN; Brailovsky CA; Madarnas P; Elhilali MM
    Anticancer Res; 1984; 4(3):209-13. PubMed ID: 6465859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BCG therapy. Its role in the treatment of tumors of the bladder].
    Patard JJ; Chopin DK; Abbou CC
    Ann Urol (Paris); 1995; 29(5):292-3. PubMed ID: 8638911
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
    Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The immunotherapy and immunoprophylaxis of bladder cancer].
    Figurin KM; Tsiganu VI
    Urol Nefrol (Mosk); 1993; (4):46-9. PubMed ID: 8310570
    [No Abstract]   [Full Text] [Related]  

  • 9. Loco-regional immunotherapy for bladder cancer.
    Kuss R; Haertig A
    Prog Clin Biol Res; 1984; 162B():321-33. PubMed ID: 6504902
    [No Abstract]   [Full Text] [Related]  

  • 10. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
    Dalbagni G
    Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCG in bladder cancer.
    Meek D
    Nurs Times; 1994 Oct 26-Nov 1; 90(43):34-5. PubMed ID: 7984457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT; Soloway MS
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer.
    Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL
    J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372
    [No Abstract]   [Full Text] [Related]  

  • 18. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract]   [Full Text] [Related]  

  • 19. [Optimizing intravesical B.C.G].
    Carballido Rodríguez JA
    Actas Urol Esp; 1998; 22(10):805-10. PubMed ID: 9949568
    [No Abstract]   [Full Text] [Related]  

  • 20. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
    Witjes JA
    Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.